title: Ventricular tachycardia in nonpostoperative pediatric patients: role of radiofrequency catheter ablation.
abstract: Experience concerning radiofrequency catheter ablation (RFCA) of ventricular tachycardia (VT) in pediatric patients is limited. In adults, success rates vary widely based on the etiology of the VT. Highest success rates have been achieved in patients without structural heart disease. Between March 1998 and December 1999, five young patients (age, 5 months to 15 years; body weight, 5.5-61.6 kg) underwent RFCA for VT at our institution [structurally normal heart (n = 4), preoperative tetralogy of Fallot (n = 1)]. Monomorphic VT was present in four children, and an infant with MIDAS syndrome had polymorphic VT. Clinical presentation varied: palpitations, n = 2, congestive heart failure, n = 3. All patients had been proven to be unresponsive to one to six (median, three) antiarrhythmic drugs. In all five patients, VT could be successfully eliminated by RFCA after a total of nine (range, 1-4) procedures. Activation mapping and pace mapping were used to identify the anatomical substrate, which was located in the right ventricle/right ventricular outflow tract in all four patients with monomorphic VT and in the left ventricular septum/left ventricular free wall in the infant with polymorphic VT. There were no significant complications in any patient. During follow-up (20-42 months), all patients are in normal sinus rhythm. Left ventricular function recovered in all three patients who had initially presented with congestive heart failure. RFCA can be effective, safe, and life saving in children with medically resistant VT who have not been operated on for congenital heart disease, even when the VT is polymorphic. Although the number of patients is small, RFCA may be the treatment of choice for symptomatic VT in pediatric patients.
authors.affiliation: The Children's Heart Program of South Carolina, Medical University of South Carolina, 165 Ashley Avenue, P.O. Box 250915, Charleston, SC 29425, USA.
authors.forename: P
authors.initials: P
authors.lastname: Laohakunakorn
authors.forename: T
authors.initials: T
authors.lastname: Paul
authors.forename: B
authors.initials: B
authors.lastname: Knick
authors.forename: A D
authors.initials: AD
authors.lastname: Blaufox
authors.forename: B
authors.initials: B
authors.lastname: Long
authors.forename: J P
authors.initials: JP
authors.lastname: Saul
mesh_terms: D000293:Adolescent; D000367:Age Factors; D000889:Anti-Arrhythmia Agents / Q000008:administration & dosage; D018780:Body Surface Potential Mapping; D017115:Catheter Ablation / Q000379:methods*; D002648:Child; D004562:Electrocardiography; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007223:Infant; D008297:Male; D011446:Prospective Studies; D012008:Recurrence; D018570:Risk Assessment; D012494:Sampling Studies; D012720:Severity of Illness Index; D017180:Tachycardia, Ventricular / Q000175:diagnosis* / Q000601:surgery*; D017211:Treatment Failure; D016896:Treatment Outcome
chemical_list: D000889:Anti-Arrhythmia Agents